002907 华森制药
已收盘 04-30 15:00:00
资讯
新帖
简况
中国中药协会副秘书长兼标准与项目部主任申诺莅临华森制药调研指导!
华森制药 · 04-25
中国中药协会副秘书长兼标准与项目部主任申诺莅临华森制药调研指导!
图解华森制药一季报:第一季度单季净利润同比增0.01%
证券之星 · 04-24
图解华森制药一季报:第一季度单季净利润同比增0.01%
华森制药(002907.SZ)发布一季度业绩,归母净利润4035.52万元,同比持平
智通财经 · 04-24
华森制药(002907.SZ)发布一季度业绩,归母净利润4035.52万元,同比持平
华森制药最新公告:2024年净利润同比增长134.66%
证券之星 · 04-24
华森制药最新公告:2024年净利润同比增长134.66%
A股午后医药板块持续走高,创新药方向继续领涨,众生药业、华森制药、富士莱涨停,百利天恒、诺诚健华、新诺威、百济神州创历史
美港电讯 · 04-22
A股午后医药板块持续走高,创新药方向继续领涨,众生药业、华森制药、富士莱涨停,百利天恒、诺诚健华、新诺威、百济神州创历史
A股中药板块异动拉升,华森制药、众生药业午后双双涨停,康缘药业、以岭药业、同仁堂、大唐药业等涨幅居前。
美港电讯 · 04-22
A股中药板块异动拉升,华森制药、众生药业午后双双涨停,康缘药业、以岭药业、同仁堂、大唐药业等涨幅居前。
【私募调研记录】相聚资本调研华森制药
证券之星 · 03-11
【私募调研记录】相聚资本调研华森制药
华森制药:公司首个特殊医学用途配方食品获得生产许可证
美港电讯 · 03-04
华森制药:公司首个特殊医学用途配方食品获得生产许可证
华森制药最新公告:公司首个特殊医学用途配方食品获得生产许可证
证券之星 · 03-04
华森制药最新公告:公司首个特殊医学用途配方食品获得生产许可证
华森制药(002907.SZ)获特殊医学用途配方食品生产许可证
智通财经 · 03-04
华森制药(002907.SZ)获特殊医学用途配方食品生产许可证
华森制药最新公告:获得螺旋藻胶囊药品补充申请批准通知书
证券之星 · 02-19
华森制药最新公告:获得螺旋藻胶囊药品补充申请批准通知书
华森制药最新公告:收到5份药品再注册批准通知书
证券之星 · 02-19
华森制药最新公告:收到5份药品再注册批准通知书
华森制药(002907.SZ):螺旋藻胶囊药品补充申请获批准
智通财经 · 02-19
华森制药(002907.SZ):螺旋藻胶囊药品补充申请获批准
华森制药(002907.SZ):“氯普噻吨片”及“阿昔洛韦片”药品再注册获批准
智通财经 · 02-19
华森制药(002907.SZ):“氯普噻吨片”及“阿昔洛韦片”药品再注册获批准
【华森制药:公司目前暂未接入DeepSeek】华森制药在投资者互动平台表示,公司目前暂未接入DeepSeek。
金融界 · 02-18
【华森制药:公司目前暂未接入DeepSeek】华森制药在投资者互动平台表示,公司目前暂未接入DeepSeek。
华森制药:公司目前暂未接入deepseek
金融界 · 02-18
华森制药:公司目前暂未接入deepseek
华森制药(002907.SZ):公司目前暂未接入deepseek
格隆汇 · 02-18
华森制药(002907.SZ):公司目前暂未接入deepseek
华森制药(002907.SZ):奥利司他胶囊药品再注册获得批准
智通财经 · 02-17
华森制药(002907.SZ):奥利司他胶囊药品再注册获得批准
华森制药最新公告:收到奥利司他胶囊药品再注册批准通知书
证券之星 · 02-17
华森制药最新公告:收到奥利司他胶囊药品再注册批准通知书
加载更多
公司概况
公司名称:
重庆华森制药股份有限公司
所属行业:
医药制造业
上市日期:
2017-10-20
主营业务:
重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是甘桔冰梅片、都梁软胶囊、六味安神胶囊、八味芪龙颗粒、痛泻宁颗粒、威地美(铝碳酸镁片)、铝碳酸镁咀嚼片、长松(聚乙二醇4000散)、胆舒软胶囊、注射用甲磺酸加贝酯、注射用奥美拉唑钠、上清片、融通(注射用阿魏酸钠)、西洛他唑片、卡托普利片、水王(螺旋藻胶囊)、阿昔洛韦片、甲硝唑片等。
发行价格:
4.53
{"stockData":{"symbol":"002907","market":"SZ","secType":"STK","nameCN":"华森制药","latestPrice":14.12,"timestamp":1745996595000,"preClose":13.95,"halted":0,"volume":8418778,"delay":0,"changeRate":0.0122,"floatShares":309000000,"shares":418000000,"eps":0.1838,"marketStatus":"已收盘","change":0.17,"latestTime":"04-30 15:00:00","open":14.12,"high":14.23,"low":13.99,"amount":119000000,"amplitude":0.0172,"askPrice":14.13,"askSize":234,"bidPrice":14.12,"bidSize":1411,"shortable":0,"etf":0,"ttmEps":0.1838,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":5,"adr":0,"adjPreClose":13.95,"symbolType":"stock","openAndCloseTimeList":[[1745976600000,1745983800000],[1745989200000,1745996400000]],"highLimit":15.35,"lowLimit":12.56,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":417596314,"isCdr":false,"pbRate":3.43,"roa":"--","peRate":76.822633,"roe":"2.4%","epsLYR":0.1837,"committee":0.306448,"marketValue":5896000000,"turnoverRate":0.0273,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2025-05-06。","floatMarketCap":4362000000},"requestUrl":"/m/hq/s/002907","defaultTab":"news","newsList":[{"id":"2530943586","title":"中国中药协会副秘书长兼标准与项目部主任申诺莅临华森制药调研指导!","url":"https://stock-news.laohu8.com/highlight/detail?id=2530943586","media":"华森制药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530943586?lang=zh_cn&edition=full","pubTime":"2025-04-25 09:31","pubTimestamp":1745544710,"startTime":"0","endTime":"0","summary":"2025年4月23日,中国中药协会副秘书长兼标准与项目部主任申诺率调研组莅临华森制药开展专题调研,围绕中医药传承创新发展、产学研协同创新等主题展开座谈。申诺副秘书长对华森制药在中药大品种培育、国际化布局及创新药研发等方面取得的成绩给予高度肯定。特别是华森制药推动甘桔冰梅片、六味安神胶囊、都梁软胶囊在新加坡获批上市,为中医药国际化提供了成功范例。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425100506a6c764d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250425100506a6c764d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["561510","002907","BK0239","562390"],"gpt_icon":0},{"id":"2530969842","title":"图解华森制药一季报:第一季度单季净利润同比增0.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2530969842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530969842?lang=zh_cn&edition=full","pubTime":"2025-04-25 02:25","pubTimestamp":1745519122,"startTime":"0","endTime":"0","summary":"证券之星消息,华森制药2025年一季报显示,公司主营收入2.39亿元,同比上升4.62%;归母净利润4035.52万元,同比上升0.01%;扣非净利润3766.74万元,同比上升1.08%;负债率12.95%,投资收益-81.13万元,财务费用-453.63万元,毛利率59.22%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042500001380.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"gpt_icon":0},{"id":"2529980375","title":"华森制药(002907.SZ)发布一季度业绩,归母净利润4035.52万元,同比持平","url":"https://stock-news.laohu8.com/highlight/detail?id=2529980375","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529980375?lang=zh_cn&edition=full","pubTime":"2025-04-24 21:00","pubTimestamp":1745499617,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)发布2025年一季度报告,第一季度,公司实现营业收入2.39亿元,同比增长4.62%。归属于上市公司股东的净利润4035.52万元,同比增长0.01%。归属于上市公司股东的扣除非经常性损益的净利润3766.74万元,同比增长1.08%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907"],"gpt_icon":0},{"id":"2529660179","title":"华森制药最新公告:2024年净利润同比增长134.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529660179","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529660179?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:41","pubTimestamp":1745491267,"startTime":"0","endTime":"0","summary":"华森制药(002907.SZ)发布2024年年度报告,公司实现营业收入7.75亿元,同比增长12.04%,净利润7673.02万元,同比增长134.66%。公司拟向全体股东每10股派发现金红利0.50元(含税)。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400033709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907"],"gpt_icon":0},{"id":"2529701316","title":"A股午后医药板块持续走高,创新药方向继续领涨,众生药业、华森制药、富士莱涨停,百利天恒、诺诚健华、新诺威、百济神州创历史","url":"https://stock-news.laohu8.com/highlight/detail?id=2529701316","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529701316?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:47","pubTimestamp":1745300842,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0028","BK0077","BK1191","BK4139","BK1500","688428","09969","002317","399300","300765","688506","BK0226","06978","ONC","BK0187","688068","688091","BK1588","LU2328871848.SGD","BK0239","002294","BK1515","159982","301258","159992","09939","688235","BK1583","BK1161","06160","BK0196","159938","BK0188","002907","LU1969619763.USD","688505","LU0588546209.SGD","LU0307460666.USD","01349","BK1574","BK0183"],"gpt_icon":0},{"id":"2529316873","title":"A股中药板块异动拉升,华森制药、众生药业午后双双涨停,康缘药业、以岭药业、同仁堂、大唐药业等涨幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2529316873","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529316873?lang=zh_cn&edition=full","pubTime":"2025-04-22 13:39","pubTimestamp":1745300355,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0188","BK0012","BK0042","BK0097","BK0086","002317","002603","BK0046","BK0196","002907","399300","BK0028","BK0113","159982","LU1688375341.USD","BK0239","600557","BK0183","BK0077","600085"],"gpt_icon":0},{"id":"2518738695","title":"【私募调研记录】相聚资本调研华森制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2518738695","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518738695?lang=zh_cn&edition=full","pubTime":"2025-03-11 08:00","pubTimestamp":1741651249,"startTime":"0","endTime":"0","summary":"根据市场公开信息及3月10日披露的机构调研信息,知名私募相聚资本近期对1家上市公司进行了调研,相关名单如下:1)华森制药 调研纪要:华森制药五大中成药收入同比增长31.44%,甘桔冰梅片同比增长54.36%,中成药板块保持稳健。多年来,相聚资本行稳致远的风格获得各大金融机构认同,已经成为四大国有银行、股份制银行、大型保险公司、头部券商等金融机构的重点合作伙伴。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025031100006608.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2516268366","title":"华森制药:公司首个特殊医学用途配方食品获得生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2516268366","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516268366?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:59","pubTimestamp":1741082355,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2516623768","title":"华森制药最新公告:公司首个特殊医学用途配方食品获得生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2516623768","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516623768?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:39","pubTimestamp":1741081178,"startTime":"0","endTime":"0","summary":"华森制药(002907.SZ)公告称,公司收到重庆市市场监督管理局核准签发的《特殊医学用途配方食品生产许可证》,产品为特易美®蛋白质组件,适用于10岁以上特定疾病或医学状况人群。该证书的获得将丰富公司产品线,提升市场竞争力,但短期内对公司业绩无重大影响。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030400030571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2516146623","title":"华森制药(002907.SZ)获特殊医学用途配方食品生产许可证","url":"https://stock-news.laohu8.com/highlight/detail?id=2516146623","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516146623?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:38","pubTimestamp":1741081100,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)公告,公司收到重庆市市场监督管理局核准签发的《特殊医学用途配方食品生产许可证》。公告显示,公司特易美®蛋白质组件是专为10岁以上,处于低蛋白血症、围术期、烧伤、感染、肿瘤等特定疾病或医学状况,亟需精准补充足量蛋白质的人群研发。每100g特易美®含高达82g的优质动植物双蛋白,其中分离乳清蛋白源自优质奶源地进口,搭配大豆分离蛋白,富含必需氨基酸,能快速且持续补氮,以维持正氮平衡,对于增强免疫力、促进组织修复和伤口愈合有重要作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1257546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2512171497","title":"华森制药最新公告:获得螺旋藻胶囊药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512171497","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512171497?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:40","pubTimestamp":1739958058,"startTime":"0","endTime":"0","summary":"华森制药公告称,公司近日收到国家药监局核准签发的关于公司产品螺旋藻胶囊的《药品补充申请批准通知书》,将变更螺旋藻胶囊药品说明书中安全性等内容。该产品为OTC甲类药品,适应症为益气养血,化痰降浊,用于气血亏虚,痰浊内蕴等症状。华森制药将进一步完善药品说明书中安全性信息的内容,有利于产品在市场终端的推广。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900031012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2512171466","title":"华森制药最新公告:收到5份药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512171466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512171466?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:40","pubTimestamp":1739958029,"startTime":"0","endTime":"0","summary":"华森制药公告称,公司近日收到重庆市药品监督管理局核准签发的5份《药品再注册批准通知书》,包括氯普噻吨片(12.5mg、15mg、25mg、50mg)和阿昔洛韦片(0.2g)。这些药品的再注册批准将确保其正常生产和销售,但短期内不会对公司经营业绩产生重大影响。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021900031010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2512417187","title":"华森制药(002907.SZ):螺旋藻胶囊药品补充申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2512417187","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512417187?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:39","pubTimestamp":1739957975,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药(002907.SZ)发布公告,公司近日收到国家药品监督管理局核准签发的关于公司产品螺旋藻胶囊的《药品补充申请批准通知书》,将变更螺旋藻胶囊药品说明书中安全性等内容。据悉,螺旋藻胶囊是华森制药研发的OTC甲类药品,采用优质螺旋藻为主要原料,经过先进的生产工艺精制而成。螺旋藻是一种天然的营养丰富的微藻,富含蛋白质、维生素、矿物质、多糖及多种生物活性物质,具有益气养血,化痰降浊的功效。本次获得《药品补充申请批准通知书》,表示公司进一步完善药品说明书中安全性信息的内容,有利于该产品在市场终端的推广。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2512797631","title":"华森制药(002907.SZ):“氯普噻吨片”及“阿昔洛韦片”药品再注册获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2512797631","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512797631?lang=zh_cn&edition=full","pubTime":"2025-02-19 17:37","pubTimestamp":1739957862,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药 发布公告,公司于近日收到重庆市药品监督管理局核准签发的5份《药品再注册批准通知书》。上述产品适应症:氯普噻吨片:用于急性和慢性精神分裂症,适用于伴有精神运动性激越、焦虑、抑郁症状的精神障碍。本次公司获得《药品再注册批准通知书》将确保上述药品的正常生产和销售,公司将严格按照要求开展相关工作,控制产品质量,持续为市场提供高品质的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1251701.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"华森制药(002907.SZ):“氯普噻吨片”及“阿昔洛韦片”药品再注册获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002907"],"gpt_icon":0},{"id":"2512718063","title":"【华森制药:公司目前暂未接入DeepSeek】华森制药在投资者互动平台表示,公司目前暂未接入DeepSeek。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512718063","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512718063?lang=zh_cn&edition=full","pubTime":"2025-02-18 15:25","pubTimestamp":1739863528,"startTime":"0","endTime":"0","summary":"华森制药在投资者互动平台表示,公司目前暂未接入DeepSeek。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/18152548224260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002907"],"gpt_icon":0},{"id":"2512805281","title":"华森制药:公司目前暂未接入deepseek","url":"https://stock-news.laohu8.com/highlight/detail?id=2512805281","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512805281?lang=zh_cn&edition=full","pubTime":"2025-02-18 15:18","pubTimestamp":1739863096,"startTime":"0","endTime":"0","summary":"金融界2月18日消息,有投资者在互动平台向华森制药提问:贵公司是否接入deepseek?公司回答表示:公司目前暂未接入deepseek。\n\n\r\n 责任编辑:磐石","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/18151848224068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002907"],"gpt_icon":0},{"id":"2512180548","title":"华森制药(002907.SZ):公司目前暂未接入deepseek","url":"https://stock-news.laohu8.com/highlight/detail?id=2512180548","media":"格隆汇","labels":["viewpoints"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512180548?lang=zh_cn&edition=full","pubTime":"2025-02-18 15:18","pubTimestamp":1739863094,"startTime":"0","endTime":"0","summary":"格隆汇2月18日丨华森制药(002907.SZ)在投资者互动平台表示,公司目前暂未接入deepseek。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/18151848224042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"华森制药(002907.SZ):公司目前暂未接入deepseek","news_tag":"viewpoints","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002907"],"gpt_icon":0},{"id":"2512946839","title":"华森制药(002907.SZ):奥利司他胶囊药品再注册获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2512946839","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512946839?lang=zh_cn&edition=full","pubTime":"2025-02-17 18:54","pubTimestamp":1739789646,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华森制药 发布公告,公司于近日收到重庆市药品监督管理局核准签发的关于公司产品奥利司他胶囊的《药品再注册批准通知书》。经审查,本品符合《药品注册管理办法》的有关规定,同意再注册。据悉,奥利司他胶囊是我国目前唯一获批的用于肥胖或体重超重患者的口服治疗药物,其主要通过减少食物中脂肪吸收来降低体重。据米内网数据显示,该产品2023年在中国网上药店终端的销售额达16亿元,同比增长101.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1250768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002907","BK0239"],"gpt_icon":0},{"id":"2512945088","title":"华森制药最新公告:收到奥利司他胶囊药品再注册批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2512945088","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512945088?lang=zh_cn&edition=full","pubTime":"2025-02-17 18:49","pubTimestamp":1739789380,"startTime":"0","endTime":"0","summary":"华森制药公告称,公司近日收到重庆市药品监督管理局核准签发的关于公司产品奥利司他胶囊的《药品再注册批准通知书》。奥利司他胶囊的药品批准文号有效期至2030年01月22日。该产品原为公司合作产品,2021年年底,公司通过与合作伙伴达成进一步约定,以自营品牌“曲畅”对奥利司他胶囊进行销售运营。目前该品种对公司营业收入与利润影响较小。短期内不会对公司经营业绩产生重大影响。以上内容为证券之星据公开信息整理,由智能算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025021700026602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002907","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1746404594708,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0609},{"period":"3month","weight":0.1498},{"period":"6month","weight":0.0421},{"period":"1year","weight":-0.0157},{"period":"ytd","weight":0.0862}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.017},{"period":"3month","weight":0.0087},{"period":"6month","weight":0.0021},{"period":"1year","weight":0.0561},{"period":"ytd","weight":-0.0217}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆华森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27712人(较上一季度增加6.36%)","perCapita":"11146股","listingDate":"2017-10-20","address":"重庆市荣昌区工业园区","registeredCapital":"41759万元","survey":" 重庆华森制药股份有限公司的主营业务是中成药、化学药的研发、生产和销售。公司的主要产品是甘桔冰梅片、都梁软胶囊、六味安神胶囊、八味芪龙颗粒、痛泻宁颗粒、威地美(铝碳酸镁片)、铝碳酸镁咀嚼片、长松(聚乙二醇4000散)、胆舒软胶囊、注射用甲磺酸加贝酯、注射用奥美拉唑钠、上清片、融通(注射用阿魏酸钠)、西洛他唑片、卡托普利片、水王(螺旋藻胶囊)、阿昔洛韦片、甲硝唑片等。","listedPrice":4.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华森制药,002907,华森制药股票,华森制药股票老虎,华森制药股票老虎国际,华森制药行情,华森制药股票行情,华森制药股价,华森制药股市,华森制药股票价格,华森制药股票交易,华森制药股票购买,华森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华森制药(002907)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华森制药(002907)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}